Syneos Health to Present Actionable Commercial Insights Designed for Biopharmaceutical Companies at BIO International Conven...
June 05 2018 - 8:55AM
Syneos Health™ (Nasdaq:SYNH), the only fully integrated
biopharmaceutical solutions organization combining a CRO (Contract
Research Organization) and CCO (Contract Commercial Organization),
will share new research and actionable commercial insights for the
biotech industry during the BIO International Convention which runs
June 4 - 7 in Boston, Massachusetts.
“Biopharmaceutical companies are facing mounting
pressure to deliver profitable growth for investors, while speeding
game-changing therapies to patients, in an environment of
increasing scrutiny,” said Michelle Keefe, President, Commercial
Solutions at Syneos Health. “This year at BIO, our goal is to bring
novel solutions to these challenges forward based on new research
and real world experience from our experts across the clinical and
commercial continuum.”
Syneos Health will lead the following
conversations at BIO, the world’s largest biotechnology industry
gathering:
Dealmakers’ Intentions: 2018 Market Outlook
Tuesday, June 5, 2:30 p.m. – 3:45 p.m., Room 205ABC, Level 2
As large biopharmaceutical companies prune their portfolios and
consider repatriation options, the expectation is running higher
than ever for an uptick in M&A this year. The tension for CEOs
in this environment is delivering a confident story about achieving
profitable growth for investors while facing an increasingly
complex marketplace. Join a highly distinguished panel of
dealmakers who will explore the impact these market forces will
have on biopharmaceutical companies as they strive to make the next
big deal. Moderator Neel Patel, Managing Director, Commercial
Strategy & Planning at Syneos Health Consulting, will share
findings from the 10th annual Syneos Health Dealmakers' Intentions
Study. Based on a survey of industry executives and business
development professionals, Dealmakers' Intentions provides insights
into what will likely drive the industry's go-forward partnering
and M&A efforts and the implications for dealmaking over the
next year or more. Analysis will include year-over-year trends,
deal metrics and broader M&A data.
Communicating Value Through the Eye of the
Beholder Wednesday, June 6, 11:00 a.m. – 12:00 p.m., Room
210A, Level 2
Value is in the eye of the beholder. Yet, the value of
game-changing medicines is coming under greater scrutiny in the
U.S. marketplace more than ever before. Companies are spending
years developing drugs, only to arrive at commercialization
disconnects with the very audiences they seek to serve. A
well-defined value proposition for payers is no longer sufficient.
Increasingly, developers must foster shared stakeholder
expectations about the value of new medicines far sooner on the
runway to commercialization.
Meg Alexander, Head of Reputation and Risk Management at Syneos
Health will moderate a panel of leading biopharma executives,
patient advocates and policy experts, providing perspectives on
effective and compliant approaches to achieving shared views on
value. Dialogue will reveal qualitative data on the resonance of
different approaches to delivering value, from access initiatives
to transparency pledges, offering actionable insights for today’s
developers.
Follow Syneos Health on LinkedIn and
Twitter to join the conversation and get a copy of
the 2018 Dealmakers’ Intentions Survey.
About Syneos HealthSyneos
Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical
solutions organization. Our company, including a Contract Research
Organization (CRO) and Contract Commercial Organization (CCO), is
purpose-built to accelerate customer performance to address modern
market realities. Created through the merger of two industry
leading companies – INC Research and inVentiv Health – we bring
together more than 21,000 clinical and commercial minds with the
ability to support customers in more than 110 countries. Together
we share insights, use the latest technologies and apply advanced
business practices to speed our customers’ delivery of important
therapies to patients. To learn more about how we are
shortening the distance from lab to life® visit
syneoshealth.com.
|
|
|
|
Contact: |
|
|
|
Investor
Relations Contact: |
|
|
Press/Media
Contact: |
Ronnie Speight |
|
|
Danielle DeForge |
Vice President,
Investor Relations |
|
|
Senior Director,
External Communications |
+1 919 745 2745 |
|
|
+1 202 210 5992 |
Investor.Relations@syneoshealth.com |
|
|
danielle.deforge@syneoshealth.com |
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024